Search

everythinglearnresearchcommunity

for

Search:↓

Upadacitinib improved multiple immune-related conditions in one patient.

A new topical treatment may prevent hair loss from cancer therapy by adjusting cell death processes in hair follicles.

Upadacitinib helped regrow hair and maintain ulcerative colitis remission.

New melanoma treatments can cause skin side effects, including skin cancer and rashes, but combining treatments may reduce these risks.

SCUBE3 is a potential target for cancer and alopecia treatment but is challenging to target due to its varied roles.

PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.

Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.

Hedgehog pathway inhibitors could be effective in treating melanoma.

Antizyme reduces tumor growth and normalizes skin cell development affected by MEK.

A new test helps find drugs to treat head and neck cancer by targeting c-Rel.

Gefitinib can cause rare scarring hair loss.

ZSYY001 is safe, well-tolerated, and shows promise for treating advanced solid tumors.

A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.

Hedgehog pathway inhibitors for advanced basal cell carcinoma can cause side effects, but managing them helps maintain treatment.

Recognizing and managing skin side effects from chemotherapy improves patient quality of life and treatment success.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Antizyme slows skin tumor growth by reducing cell growth in mice.

The protein ER71/ETV2 helps regrow hair after chemotherapy by improving the growth of new blood vessels.

EGFR inhibitors can cause skin issues, but managing them is important for treatment success.

Longer immunotherapy treatment may improve outcomes for Merkel cell carcinoma patients.

Stopping gefitinib improved scalp condition in a woman with lung cancer.

Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.

Prostaglandin E2 helps prevent hair loss from radiotherapy by protecting hair cells.

EGFR inhibitors for lung cancer can cause severe skin issues.

Enhancing immune response can improve cancer treatment effectiveness.

Rituximab leads to longer remission and fewer side effects than cyclophosphamide.

XMU-MP-1 stops cell growth in a human mini-organ and reduces the effectiveness of the chemotherapy drug paclitaxel.

The document concludes that ERBB2 mutations are common in extramammary Paget disease and may respond to systemic treatments like cancer immunotherapy.